Coronary Artery Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
Implementation of a national AI technology program on cardiovascular outcomes and the health system.
Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes.
2024 ESC Guidelines for the management of chronic coronary syndromes.
Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.
The Role of Stem Cells in the Treatment of Cardiovascular Diseases.
Approval: Rivaroxaban Viatris (previously Rivaroxaban Mylan) (EMA)
Approval: Rivaroxaban Accord (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity.
- 1 industry development reported.
- Q4 2026Non-commercial Clinical Trial of Statins CAncer Preventive and Pleiotropic TherApy IN Smokers With Chronic Obstructive Pulmonary Disease (COPD)
- Q1 2027Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPT
- Q2 2027EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
- Q2 2027Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia: A Prospective Multicenter Study
- Q2 2027Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
Research HighlightsViewHide
Clinical MilestonesView all 11Hide
- 2026-06-12Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and ColchicineResults expected Q2 2027
- 2026-05-15Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPTResults expected Q1 2027
- 2026-04-21Non-commercial Clinical Trial of Statins CAncer Preventive and Pleiotropic TherApy IN Smokers With Chronic Obstructive Pulmonary Disease (COPD)Results expected Q4 2026
- 2026-03-23Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia: A Prospective Multicenter StudyResults expected Q2 2027
- 2025-10-06EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial InfarctionResults expected Q2 2027
- 2026-05-31Effect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - A Pilot Randomized Controlled TrialCompleted
- 2026-05-30Escalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary InterventionCompleted
- 2026-05-22Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real StudyPrimary completion
- 2030-12-01A Multicenter, Randomized, Outcomes Assessor Blind, Parallel Controlled Trial to Evaluate the Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After Coronary Artery Bypass GraftingWithdrawn
- 2026-05-16Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical TrialTerminated
- 2026-02-26Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized StudyTerminated
Industry & MarketViewHide
- 2026-07-15Deaths from coronary artery disease have fallen, but more progress is within reachIndustry · STAT News
- 2030-12-01ClinicalA Multicenter, Randomized, Outcomes Assessor Blind, Parallel Controlled Trial to Evaluate the Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After Coronary Artery Bypass GraftingWithdrawn
- 2026-07-15IndustryDeaths from coronary artery disease have fallen, but more progress is within reachIndustry · STAT News
- 2026-06-12ClinicalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and ColchicineResults expected Q2 2027
- 2026-05-31ClinicalEffect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - A Pilot Randomized Controlled TrialCompleted
- 2026-05-30ClinicalEscalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary InterventionCompleted
- 2026-05-22ClinicalAcute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real StudyPrimary completion
- 2026-05-16ClinicalEffect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical TrialTerminated
- 2026-05-15ClinicalIschemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPTResults expected Q1 2027
- 2026-04-21ClinicalNon-commercial Clinical Trial of Statins CAncer Preventive and Pleiotropic TherApy IN Smokers With Chronic Obstructive Pulmonary Disease (COPD)Results expected Q4 2026
- 2026-03-23ClinicalManagement of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia: A Prospective Multicenter StudyResults expected Q2 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus… (2021)
Approval — Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the s… (2017)
Approval — Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reductio… (2015)
Approval — Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the s… (2015)
Approval — This medicinal product is for diagnostic use only. Luminity is an ultrasound contrast-enh… (2006)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Coronary Artery Disease25
- Cardiovascular Diseases8
- Computed Tomography Angiography6
- Coronary Angiography5
- Percutaneous Coronary Intervention4
- Gastrointestinal Microbiome3
- Plaque, Atherosclerotic3
- Atrial Fibrillation2
Leading journals6
- Circulation8
- European heart journal8
- The New England journal of medicine6
- Cardiovascular diabetology2
- International journal of molecular sciences2
- Journal of the American College of Cardiology2
Leading researchers8
- Aragam KG3
- Bangalore S3
- Bhatt DL3
- Blankstein R3
- Earls JP3
- Ellinor PT3
- Greenwood JP3
- Mehran R3
Affiliations (unnormalised)6
- Brigham and Women's Hospital7
- Stanford University School of Medicine5
- Harvard Medical School4
- University of Cambridge4
- University of Oxford4
- Cardiovascular Research Center3
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Coronary artery disease is a pathological process affecting the coronary arteries. It may arise from congenital abnormalities, atherosclerotic disease, or non-atherosclerotic causes. The literature also treats it as a major form of atherosclerotic cardiovascular disease with chronic and acute clinical phases.
The supplied grounding supports atherosclerosis as a major cause, and also notes that coronary artery disease may derive from congenital abnormality or non-atherosclerotic causes. Chronic kidney disease is described as a major risk factor and is associated with traditional contributors such as diabetes and hypertension. The literature also links smoking and modifiable lifestyle factors to disease risk and prevention.
The pathophysiology is described as an inflammatory disorder rather than simply a cholesterol storage disease. Arterial remodeling and nonstenotic plaque biology are emphasized, and plaque disruption can occur even without critical stenosis. Macrophages are highlighted as central to plaque development, local inflammation, and thrombosis, while vascular cell migration and proliferation are also implicated.
Traditional risk factors include diabetes, hypertension, smoking, and other lifestyle-related factors used in risk prediction. Chronic kidney disease is specifically identified as a major risk factor, with additional nontraditional contributors such as inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. Genetic susceptibility is also supported by genome-wide association findings and polygenic risk score literature.
Management includes revascularization for relief of ischemia. The literature also supports aggressive management of modifiable risk factors alongside revascularization, and drug therapy is represented by antiplatelet agents such as clopidogrel and ticlopidine. Diagnostic and management approaches also include fractional flow reserve and other diagnostic imaging or diagnostic modalities.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.